ARAZLO Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6517847 | BAUSCH | Topical gel delivery system |
Aug, 2020
(3 years ago) | |
| US11679116 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(12 years from now) | |
| US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(14 years from now) | |
Arazlo is owned by Bausch.
Arazlo contains Tazarotene.
Arazlo has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Arazlo are:
- US6517847
Arazlo was authorised for market use on 18 December, 2019.
Arazlo is available in lotion;topical dosage forms.
Arazlo can be used as topical treatment of acne vulgaris in patients 9 years of age and older.
The generics of Arazlo are possible to be released after 11 May, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION;TOPICAL
How can I launch a generic of ARAZLO before it's drug patent expiration?
More Information on Dosage
ARAZLO family patents
